

Rui Henrique

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8699132/publications.pdf>

Version: 2024-02-01

374
papers

12,104
citations

30551

56
h-index

60403

85
g-index

388
all docs

388
docs citations

388
times ranked

16895
citing authors

#	ARTICLE	IF	CITATIONS
1	Epigenetic Editing in Prostate Cancer: Challenges and Opportunities. <i>Epigenetics</i> , 2022, 17, 564-588.	1.3	4
2	Colorectal Screening Program in Northern Portugal: First Findings. <i>Acta Medica Portuguesa</i> , 2022, 35, 164-169.	0.2	4
3	Size reduction and decreased enhancement of benign breast fibroadenoma on contrast-enhanced mammography during neoadjuvant chemotherapy. <i>Diagnostic and Interventional Imaging</i> , 2022, 103, 121-122.	1.8	0
4	Integration of Automatic Text Mining and Genomic and Proteomic Analysis to Unravel Prostate Cancer Biomarkers. <i>Journal of Proteome Research</i> , 2022, 21, 447-458.	1.8	5
5	Cadherin switches during epithelial-mesenchymal transition: CDH4/RCAD downregulation reduces bladder cancer progression. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 135-149.	2.1	2
6	Downregulation of m ⁶ A writer complex member METTL14 in bladder urothelial carcinoma suppresses tumor aggressiveness. <i>Molecular Oncology</i> , 2022, 16, 1841-1856.	2.1	10
7	The modulatory role of internet-supported mindfulness-based cognitive therapy on extracellular vesicles and psychological distress in people who have had cancer: a protocol for a two-armed randomized controlled study. <i>Trials</i> , 2022, 23, 118.	0.7	5
8	Ki67 and LSD1 Expression in Testicular Germ Cell Tumors Is Not Associated with Patient Outcome: Investigation Using a Digital Pathology Algorithm. <i>Life</i> , 2022, 12, 264.	1.1	3
9	LiKidMiRs: A ddPCR-Based Panel of 4 Circulating miRNAs for Detection of Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 858.	1.7	15
10	Extracellular vesicle-contained microRNAs in prostate cancer: From pathophysiology to emerging translational opportunities. , 2022, , 291-299.		0
11	Application of Proteogenomics to Urine Analysis towards the Identification of Novel Biomarkers of Prostate Cancer: An Exploratory Study. <i>Cancers</i> , 2022, 14, 2001.	1.7	8
12	G9a inhibition by CM-272: Developing a novel anti-tumoral strategy for castration-resistant prostate cancer using 2D and 3D in vitro models. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 113031.	2.5	9
13	One sample fits all: a microfluidic-assisted methodology for label-free isolation of CTCs with downstream methylation analysis of cfDNA in lung cancer. <i>Biomaterials Science</i> , 2022, 10, 3296-3308.	2.6	2
14	From Therapy Resistance to Targeted Therapies in Prostate Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	10
15	DNA Methylation Biomarkers for Prediction of Response to Platinum-Based Chemotherapy: Where Do We Stand?. <i>Cancers</i> , 2022, 14, 2918.	1.7	6
16	Epigenetically-regulated miR-30a/c-5p directly target TWF1 and hamper ccRCC cell aggressiveness. <i>Translational Research</i> , 2022, 249, 110-127.	2.2	5
17	PP1 catalytic isoforms are differentially expressed and regulated in human prostate cancer. <i>Experimental Cell Research</i> , 2022, 418, 113282.	1.2	2
18	Epigenetic alterations as therapeutic targets in Testicular Germ Cell Tumours : current and future application of "epidrugs"™. <i>Epigenetics</i> , 2021, 16, 353-372.	1.3	19

#	ARTICLE	IF	CITATIONS
19	Enhanced Ultraviolet Spectroscopy by Optical Clearing for Biomedical Applications. IEEE Journal of Selected Topics in Quantum Electronics, 2021, 27, 1-8.	1.9	20
20	Merkel cell carcinoma metastatic to the testis: report of a rare diagnosis and review of the literature. Autopsy and Case Reports, 2021, 11, e2020198.	0.2	2
21	Targeting Germ Cell Tumors with the Newly Synthesized Flavanone-Derived Compound MLo1302 Efficiently Reduces Tumor Cell Viability and Induces Apoptosis and Cell Cycle Arrest. Pharmaceutics, 2021, 13, 73.	2.0	10
22	Gastric Diffuse Large B-Cell Lymphoma: A Single-Center 9-Year Experience. Indian Journal of Hematology and Blood Transfusion, 2021, 37, 492-496.	0.3	4
23	Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer. Communications Biology, 2021, 4, 119.	2.0	18
24	Bioinformatic analysis of dysregulated proteins in prostate cancer patients reveals putative urinary biomarkers and key biological pathways. Medical Oncology, 2021, 38, 9.	1.2	6
25	Metabolic regulation in urological tumors: Interplay with epigenetics and epitranscriptomics. , 2021, , 107-145.		0
26	Abstract PS2-31: Circulating miR-99a-5p expression in plasma: A potential biomarker for early diagnosis of breast cancer. , 2021, , .		0
27	Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer. ESMO Open, 2021, 6, 100039.	2.0	22
28	Discovery of Volatile Biomarkers for Bladder Cancer Detection and Staging through Urine Metabolomics. Metabolites, 2021, 11, 199.	1.3	27
29	Liquid Biopsies in the Clinical Management of Germ Cell Tumor Patients: State-of-the-Art and Future Directions. International Journal of Molecular Sciences, 2021, 22, 2654.	1.8	13
30	Genome-Wide DNA Methylation Profiling of Esophageal Squamous Cell Carcinoma from Global High-Incidence Regions Identifies Crucial Genes and Potential Cancer Markers. Cancer Research, 2021, 81, 2612-2624.	0.4	27
31	Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy. Clinical Epigenetics, 2021, 13, 63.	1.8	34
32	Secreted Extracellular Vesicle Molecular Cargo as a Novel Liquid Biopsy Diagnostics of Central Nervous System Diseases. International Journal of Molecular Sciences, 2021, 22, 3267.	1.8	13
33	Urinary Extracellular Vesicles as Potential Biomarkers for Urologic Cancers: An Overview of Current Methods and Advances. Cancers, 2021, 13, 1529.	1.7	21
34	Promoter methylation of DNA homologous recombination genes is predictive of the responsiveness to PARP inhibitor treatment in testicular germ cell tumors. Molecular Oncology, 2021, 15, 846-865.	2.1	15
35	Urinary Volatilomics Unveils a Candidate Biomarker Panel for Noninvasive Detection of Clear Cell Renal Cell Carcinoma. Journal of Proteome Research, 2021, 20, 3068-3077.	1.8	23
36	Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation. Cancers, 2021, 13, 2101.	1.7	14

#	ARTICLE	IF	CITATIONS
37	Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples. <i>Clinical Epigenetics</i> , 2021, 13, 70.	1.8	13
38	Diffuse reflectance and machine learning techniques to differentiate colorectal cancer <i>in vivo</i> . <i>Chaos</i> , 2021, 31, 053118.	1.0	11
39	Protein Aggregation Patterns Inform about Breast Cancer Response to Antiestrogens and Reveal the RNA Ligase RTCB as Mediator of Acquired Tamoxifen Resistance. <i>Cancers</i> , 2021, 13, 3195.	1.7	12
40	miR-424 loaded circulating small extracellular vesicles: Novel biomarkers associated with aggressive prostate cancer. <i>European Urology</i> , 2021, 79, S597.	0.9	0
41	Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer. <i>Cancers</i> , 2021, 13, 2848.	1.7	14
42	Hydralazine and Panobinostat Attenuate Malignant Properties of Prostate Cancer Cell Lines. <i>Pharmaceuticals</i> , 2021, 14, 670.	1.7	11
43	Evidence of psychological and biological effects of structured Mindfulness-Based Interventions for cancer patients and survivors: A meta-review. <i>Psycho-Oncology</i> , 2021, 30, 1836-1848.	1.0	17
44	Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer. <i>Biomedicines</i> , 2021, 9, 976.	1.4	6
45	Bridging the Gaps between Circulating Tumor Cells and DNA Methylation in Prostate Cancer. <i>Cancers</i> , 2021, 13, 4209.	1.7	6
46	The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 268.	3.5	27
47	Morphological and molecular heterogeneity in testicular germ cell tumors: implications for dedicated investigations. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 865-866.	1.4	3
48	Performance of DNA methylation-based biomarkers in the cervical cancer screening program of northern Portugal: A feasibility study. <i>International Journal of Cancer</i> , 2021, 149, 1916-1925.	2.3	7
49	Deregulation of N6-Methyladenosine RNA Modification and Its Erasers FTO/ALKBH5 among the Main Renal Cell Tumor Subtypes. <i>Journal of Personalized Medicine</i> , 2021, 11, 996.	1.1	20
50	MP33-02 UNRAVELING GENOMIC ALTERATIONS OF CRIBRIFORM AND INTRADUCTAL PROSTATE CANCER. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
51	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021, 15, 2507-2543.	2.1	7
52	Anti-neoplastic and demethylating activity of a newly synthesized flavanone-derived compound in Renal Cell Carcinoma cell lines. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111681.	2.5	2
53	IgA nephropathy in IgG kappa multiple myeloma. <i>Porto Biomedical Journal</i> , 2021, 6, e142.	0.4	0
54	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , The, 2021, 22, 1618-1631.	5.1	48

#	ARTICLE	IF	CITATIONS
55	Epigenetic extracellular vesicle-based biomarkers for urological malignancies: is the hope worth the hype?. <i>Epigenomics</i> , 2021, 13, 1514-1521.	1.0	2
56	Unveiling the World of Circulating and Exosomal microRNAs in Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5252.	1.7	8
57	Tissue Spectroscopy and Optical Clearing of Colorectal Mucosa in the Pursuit of New Cancer Diagnostic Approaches. <i>Journal of Biomedical Photonics and Engineering</i> , 2021, 7, 040302.	0.4	2
58	Comprehensive Metabolomics and Lipidomics Profiling of Prostate Cancer Tissue Reveals Metabolic Dysregulations Associated with Disease Development. <i>Journal of Proteome Research</i> , 2021, , .	1.8	11
59	Prognostic Value of Histone Modifying Enzyme EZH2 in RCHOP-Treated Diffuse Large B-Cell Lymphoma and High Grade B-Cell Lymphoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1384.	1.1	0
60	Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Mass Spectrometry Studies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13605.	1.8	3
61	Widening the spectrum of Lynch syndrome: first report of testicular seminoma attributable to MSH2 loss. <i>Histopathology</i> , 2020, 76, 486-489.	1.6	5
62	Differential expression of DNA methyltransferases and demethylases among the various testicular germ cell tumor subtypes. <i>Epigenomics</i> , 2020, 12, 1579-1592.	1.0	9
63	Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7427.	1.8	24
64	Efficacy of HDAC Inhibitors Belinostat and Panobinostat against Cisplatin-Sensitive and Cisplatin-Resistant Testicular Germ Cell Tumors. <i>Cancers</i> , 2020, 12, 2903.	1.7	20
65	Assessment of HER2 Protein Overexpression and Gene Amplification in Renal Collecting Duct Carcinoma: Therapeutic Implication. <i>Cancers</i> , 2020, 12, 3345.	1.7	3
66	Lipofuscin-Type Pigment as a Marker of Colorectal Cancer. <i>Electronics (Switzerland)</i> , 2020, 9, 1805.	1.8	8
67	Development of Sensitive Droplet Digital PCR Assays for Detecting Urinary TERT Promoter Mutations as Non-Invasive Biomarkers for Detection of Urothelial Cancer. <i>Cancers</i> , 2020, 12, 3541.	1.7	27
68	A DNA methylation-based test for esophageal cancer detection. <i>Biomarker Research</i> , 2020, 8, 68.	2.8	11
69	Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 3911.	1.0	5
70	Practicability of clinical application of bladder cancer molecular classification and additional value of epithelial-to-mesenchymal transition: prognostic value of vimentin expression. <i>Journal of Translational Medicine</i> , 2020, 18, 303.	1.8	11
71	Renal Cell Tumors: Uncovering the Biomarker Potential of ncRNAs. <i>Cancers</i> , 2020, 12, 2214.	1.7	12
72	Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study. <i>Advances in Anatomic Pathology</i> , 2020, 27, 303-310.	2.4	10

#	ARTICLE	IF	CITATIONS
73	A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers. <i>Cancers</i> , 2020, 12, 2017.	1.7	18
74	DNA Methylation as a Therapeutic Target for Bladder Cancer. <i>Cells</i> , 2020, 9, 1850.	1.8	35
75	Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression. <i>Cancer Immunology Research</i> , 2020, 8, 1407-1425.	1.6	33
76	Clinical implications of the American Joint Committee on Cancer (AJCC) 8th edition update in seminoma pT1 subclassification. <i>BMC Urology</i> , 2020, 20, 127.	0.6	5
77	JmjC-KDMs KDM3A and KDM6B modulate radioresistance under hypoxic conditions in esophageal squamous cell carcinoma. <i>Cell Death and Disease</i> , 2020, 11, 1068.	2.7	33
78	Epigenetic Alterations in Oesophageal Cancer: Expression and Role of the Involved Enzymes. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3522.	1.8	7
79	Repurposing Old Drugs into New Epigenetic Inhibitors: Promising Candidates for Cancer Treatment?. <i>Pharmaceutics</i> , 2020, 12, 410.	2.0	20
80	p53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome. <i>Andrology</i> , 2020, 8, 1233-1242.	1.9	14
81	New findings on urinary prostate cancer metabolome through combined GC-MS and 1H NMR analytical platforms. <i>Metabolomics</i> , 2020, 16, 70.	1.4	24
82	MicroRNA-30a-5pme: a novel diagnostic and prognostic biomarker for clear cell renal cell carcinoma in tissue and urine samples. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 98.	3.5	34
83	DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types. <i>Cells</i> , 2020, 9, 624.	1.8	108
84	The metabolic landscape of urological cancers: New therapeutic perspectives. <i>Cancer Letters</i> , 2020, 477, 76-87.	3.2	14
85	Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives. <i>Cancers</i> , 2020, 12, 1601.	1.7	37
86	Targeting the Immune system and Epigenetic Landscape of Urological Tumors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 829.	1.8	15
87	A Multiplex Test Assessing MiR663ame and VIMme in Urine Accurately Discriminates Bladder Cancer from Inflammatory Conditions. <i>Journal of Clinical Medicine</i> , 2020, 9, 605.	1.0	7
88	Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence. <i>Molecular Medicine</i> , 2020, 26, 22.	1.9	3
89	Sirtuins™ Deregulation in Bladder Cancer: SIRT7 Is Implicated in Tumor Progression through Epithelial to Mesenchymal Transition Promotion. <i>Cancers</i> , 2020, 12, 1066.	1.7	21
90	Lactate Increases Renal Cell Carcinoma Aggressiveness through Sirtuin 1-Dependent Epithelial Mesenchymal Transition Axis Regulation. <i>Cells</i> , 2020, 9, 1053.	1.8	26

#	ARTICLE	IF	CITATIONS
91	Volatilomics Reveals Potential Biomarkers for Identification of Renal Cell Carcinoma: An In Vitro Approach. <i>Metabolites</i> , 2020, 10, 174.	1.3	9
92	The inflammation-related biomarker CXCR7 independently predicts patient outcome after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 794.e17-794.e27.	0.8	2
93	Analysis of Epigenetic Alterations in Homologous Recombination DNA Repair Genes in Male Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2715.	1.8	4
94	VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer. <i>Cancers</i> , 2020, 12, 771.	1.7	59
95	RAD51Bme Levels as a Potential Predictive Biomarker for PD-1 Blockade Response in Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 1000.	1.0	6
96	Measurement of optical properties of normal and pathological human liver tissue from deep-UV to NIR. , 2020, , .		4
97	Can epigenetic and inflammatory biomarkers identify clinically aggressive prostate cancer?. <i>World Journal of Clinical Oncology</i> , 2020, 11, 43-52.	0.9	12
98	<i>RAD51B</i>_{me} as predictive biomarker for PD-1 blockade response in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e15235-e15235.	0.8	0
99	Signaling Pathways Involved in Kidney and Urinary Tract Physiology and Pathology. , 2020, , 163-193.		0
100	Targeting chromatin remodelers in urological tumors. , 2020, , 179-213.		0
101	Kinetics of Optical Properties of Colorectal Muscle During Optical Clearing. <i>IEEE Journal of Selected Topics in Quantum Electronics</i> , 2019, 25, 1-8.	1.9	16
102	High-Risk human papillomavirus genotype distribution in the Northern region of Portugal: Data from regional cervical cancer screening program. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2019, 8, 100179.	4.5	16
103	Moving tissue spectral window to the deepâ€ ultraviolet via optical clearing. <i>Journal of Biophotonics</i> , 2019, 12, e201900181.	1.1	15
104	Detailed Characterization of Immune Cell Infiltrate and Expression of Immune Checkpoint Molecules PD-L1/CTLA-4 and MMR Proteins in Testicular Germ Cell Tumors Disclose Novel Disease Biomarkers. <i>Cancers</i> , 2019, 11, 1535.	1.7	42
105	Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine. <i>British Journal of Cancer</i> , 2019, 121, 857-868.	2.9	74
106	Higher IL-6 peri-tumoural expression is associated with gastro-intestinal neuroendocrine tumour progression. <i>Pathology</i> , 2019, 51, 593-599.	0.3	12
107	Predictive and Prognostic Value of Selected MicroRNAs in Luminal Breast Cancer. <i>Frontiers in Genetics</i> , 2019, 10, 815.	1.1	35
108	Circulating MicroRNAs as Biomarkers for Prostate Cancer Detection and Metastasis Development Prediction. <i>Frontiers in Oncology</i> , 2019, 9, 900.	1.3	69

#	ARTICLE	IF	CITATIONS
109	XIST-Promoter Demethylation as Tissue Biomarker for Testicular Germ Cell Tumors and Spermatogenesis Quality. <i>Cancers</i> , 2019, 11, 1385.	1.7	24
110	Subtyping Lung Cancer Using DNA Methylation in Liquid Biopsies. <i>Journal of Clinical Medicine</i> , 2019, 8, 1500.	1.0	37
111	Disseminated Well-Differentiated Gastro-Entero-Pancreatic Tumors Are Associated with Metabolic Syndrome. <i>Journal of Clinical Medicine</i> , 2019, 8, 1479.	1.0	9
112	Predicting resistance to endocrine therapy in breast cancer: It's time for epigenetic biomarkers (Review). <i>Oncology Reports</i> , 2019, 41, 1431-1438.	1.2	13
113	GC-MS Metabolomics Reveals Distinct Profiles of Low- and High-Grade Bladder Cancer Cultured Cells. <i>Metabolites</i> , 2019, 9, 18.	1.3	15
114	Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer. <i>EBioMedicine</i> , 2019, 44, 431-438.	2.7	41
115	E-cadherin clone 36 nuclear staining dictates adverse disease outcome in lobular breast cancer patients. <i>Modern Pathology</i> , 2019, 32, 1574-1586.	2.9	7
116	Measuring optical properties of human liver between 400 and 1000 nm. <i>Quantum Electronics</i> , 2019, 49, 13-19.	0.3	13
117	In-air production of 3D co-culture tumor spheroid hydrogels for expedited drug screening. <i>Acta Biomaterialia</i> , 2019, 94, 392-409.	4.1	72
118	Successful treatment of refractory chylous ascites due to follicular lymphoma with very low-dose radiotherapy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2019, 24, 344-346.	0.3	4
119	Histone variant MacroH2A1 is downregulated in prostate cancer and influences malignant cell phenotype. <i>Cancer Cell International</i> , 2019, 19, 112.	1.8	13
120	The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma. <i>Genes</i> , 2019, 10, 264.	1.0	18
121	m6A RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance. <i>Journal of Translational Medicine</i> , 2019, 17, 79.	1.8	55
122	Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 367-375.	1.5	10
123	The nonsense mutation <i>MSH2</i> c.2152C>T shows a founder effect in Portuguese Lynch syndrome families. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 657-664.	1.5	3
124	Is it "hybrid" or "intermediate" more than just a semantic issue in oncocytic renal cell tumors. <i>Annals of Translational Medicine</i> , 2019, 7, S356-S356.	0.7	0
125	The Critical Role of Hypoxic Microenvironment and Epigenetic Deregulation in Esophageal Cancer Radioresistance. <i>Genes</i> , 2019, 10, 927.	1.0	22
126	Overexpression of circulating MiR-30b-5p identifies advanced breast cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 435.	1.8	27

#	ARTICLE	IF	CITATIONS
127	Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel. <i>Clinical Epigenetics</i> , 2019, 11, 175.	1.8	40
128	Expression of EMT-Related Genes CAMK2N1 and WNT5A is increased in Locally Invasive and Metastatic Prostate Cancer. <i>Journal of Cancer</i> , 2019, 10, 5915-5925.	1.2	18
129	Identification and Validation Model for Informative Liquid Biopsy-Based microRNA Biomarkers: Insights from Germ Cell Tumor In Vitro, In Vivo and Patient-Derived Data. <i>Cells</i> , 2019, 8, 1637.	1.8	73
130	The Role of DNA/Histone Modifying Enzymes and Chromatin Remodeling Complexes in Testicular Germ Cell Tumors. <i>Cancers</i> , 2019, 11, 6.	1.7	26
131	A robust <i>ex vivo</i> method to evaluate the diffusion properties of agents in biological tissues. <i>Journal of Biophotonics</i> , 2019, 12, e201800333.	1.1	23
132	MSH2 Expression and Resistance to Cisplatin in Muscle-invasive Bladder Cancer: A Mix of Progress and Challenges. <i>European Urology</i> , 2019, 75, 251-252.	0.9	10
133	Epigenetic Mechanisms Influencing Epithelial to Mesenchymal Transition in Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 297.	1.8	33
134	Human Germ Cell Tumors are Developmental Cancers: Impact of Epigenetics on Pathobiology and Clinic. <i>International Journal of Molecular Sciences</i> , 2019, 20, 258.	1.8	93
135	Volatile metabolomic signature of bladder cancer cell lines based on gas chromatography-mass spectrometry. <i>Metabolomics</i> , 2018, 14, 62.	1.4	32
136	Germ cell tumour subtypes display differential expression of microRNA371a-3p. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2018, 373, 20170338.	1.8	46
137	Discrimination between the human prostate normal and cancer cell exometabolome by GC-MS. <i>Scientific Reports</i> , 2018, 8, 5539.	1.6	50
138	Contribution of <i>MLH1</i> constitutional methylation for Lynch syndrome diagnosis in patients with tumor <i>MLH1</i> downregulation. <i>Cancer Medicine</i> , 2018, 7, 433-444.	1.3	28
139	Correction to: Abstracts. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 297-297.	1.4	0
140	Influence of <i>HOTAIR</i> rs920778 and rs12826786 genetic variants on prostate cancer risk and progression-free survival. <i>Biomarkers in Medicine</i> , 2018, 12, 257-264.	0.6	16
141	MicroRNA-27a-5p regulation by promoter methylation and MYC signaling in prostate carcinogenesis. <i>Cell Death and Disease</i> , 2018, 9, 167.	2.7	48
142	A multiplatform approach identifies miR-152-3p as a common epigenetically regulated onco-suppressor in prostate cancer targeting TMEM97. <i>Clinical Epigenetics</i> , 2018, 10, 40.	1.8	39
143	Correction to: Abstracts. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 303-303.	1.4	0
144	Methylation-Specific PCR. <i>Methods in Molecular Biology</i> , 2018, 1708, 447-472.	0.4	22

#	ARTICLE	IF	CITATIONS
145	A DNA Methylation-Based Test for Breast Cancer Detection in Circulating Cell-Free DNA. <i>Journal of Clinical Medicine</i> , 2018, 7, 420.	1.0	46
146	The Emerging Role of Epitranscriptomics in Cancer: Focus on Urological Tumors. <i>Genes</i> , 2018, 9, 552.	1.0	68
147	Integrative epigenetic taxonomy of primary prostate cancer. <i>Nature Communications</i> , 2018, 9, 4900.	5.8	107
148	Oncogenic potential of CHAF1A in gastric cancer: A novel link with Helicobacter pylori-driven carcinogenesis?. <i>EBioMedicine</i> , 2018, 38, 3-4.	2.7	5
149	DNA methylation profiling as a tool for testicular germ cell tumors subtyping. <i>Epigenomics</i> , 2018, 10, 1511-1523.	1.0	40
150	Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women. <i>Cancers</i> , 2018, 10, 357.	1.7	43
151	Interplay between sympathetic nervous system and inflammation in aseptic loosening of hip joint replacement. <i>Scientific Reports</i> , 2018, 8, 16044.	1.6	9
152	Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients. <i>Clinical Epigenetics</i> , 2018, 10, 132.	1.8	21
153	Hybrid oncocytic/chromophobe renal cell tumor: An integrated genetic and epigenetic characterization of a case. <i>Experimental and Molecular Pathology</i> , 2018, 105, 352-356.	0.9	3
154	Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets. <i>Frontiers in Genetics</i> , 2018, 9, 427.	1.1	88
155	Evaluation of prostate cancer volatilome: An in vitro approach. <i>Toxicology Letters</i> , 2018, 295, S268.	0.4	0
156	Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2018, 10, 293.	1.7	37
157	Tissue optical clearing as a diagnostic tool for tissue pathology differentiation. , 2018, , .		1
158	<scp>FOXA</scp>1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome. <i>Molecular Oncology</i> , 2018, 12, 1884-1894.	2.1	19
159	Quantitative Analysis of Seven New Prostate Cancer Biomarkers and the Potential Future of the â€Biomarker Laboratoryâ€™. <i>Diagnostics</i> , 2018, 8, 49.	1.3	8
160	Targeting DNA Methyltransferases in Urological Tumors. <i>Frontiers in Pharmacology</i> , 2018, 9, 366.	1.6	29
161	Testicular germ cell tumors: revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists. <i>Human Pathology</i> , 2018, 82, 113-124.	1.1	62
162	GC-MS-Based Endometabolome Analysis Differentiates Prostate Cancer from Normal Prostate Cells. <i>Metabolites</i> , 2018, 8, 23.	1.3	22

#	ARTICLE	IF	CITATIONS
163	Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 473, 443-452.	1.4	7
164	A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway. <i>Journal of Translational Medicine</i> , 2018, 16, 45.	1.8	39
165	Profiling DNA Methylation Based on Next-Generation Sequencing Approaches: New Insights and Clinical Applications. <i>Genes</i> , 2018, 9, 429.	1.0	108
166	Prognostic value of histone marks H3K27me3 and H3K9me3 and modifying enzymes EZH2, SETDB1 and LSD-1 in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 2127-2137.	1.2	28
167	High immunoexpression of Ki67, EZH2, and SMYD3 in diagnostic prostate biopsies independently predicts outcome in patients with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 161.e7-161.e17.	0.8	41
168	Kinetics of optical properties of human colorectal tissues during optical clearing: a comparative study between normal and pathological tissues. <i>Journal of Biomedical Optics</i> , 2018, 23, 1.	1.4	17
169	Detection of microsatellite instability (MSI) in colorectal cancer samples with a novel set of highly sensitive markers by means of the Idylla MSI Test prototype.. <i>Journal of Clinical Oncology</i> , 2018, 36, e15639-e15639.	0.8	12
170	Postâ€transplant lymphoproliferative disorder in hematopoietic stem cell transplant patients: A single center retrospective study between 2005 and 2012. <i>Molecular Medicine Reports</i> , 2018, 18, 4650-4656.	1.1	2
171	Optical properties of colorectal muscle in visible/NIR range. , 2018, , .		3
172	The epigenetics of testicular germ cell tumors: looking for novel disease biomarkers. <i>Epigenomics</i> , 2017, 9, 155-169.	1.0	37
173	ALKâ€negative anaplastic large cell lymphoma with urinary bladder involvement diagnosed in urine cytology: A case report and literature review. <i>Diagnostic Cytopathology</i> , 2017, 45, 354-358.	0.5	6
174	MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors. <i>Molecular Cancer</i> , 2017, 16, 26.	7.9	64
175	MicroRNA promoter methylation: a new tool for accurate detection of urothelial carcinoma. <i>British Journal of Cancer</i> , 2017, 116, 634-639.	2.9	18
176	The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelialâ€mesenchymal transition in mammary epithelial and in breast cancer cells. <i>Cancer Letters</i> , 2017, 396, 42-52.	3.2	29
177	Downregulation of miR-130b~301b cluster is mediated by aberrant promoter methylation and impairs cellular senescence in prostate cancer. <i>Journal of Hematology and Oncology</i> , 2017, 10, 43.	6.9	48
178	Identification of somatic <i><sc>TERT</sc></i> promoter mutations in familial nonmedullary thyroid carcinomas. <i>Clinical Endocrinology</i> , 2017, 87, 394-399.	1.2	23
179	Comparative study of the optical properties of colon mucosa and colon precancerous polyps between 400 and 1000 nm. <i>Proceedings of SPIE</i> , 2017, , .	0.8	8
180	ASF1A in Gastric and Colorectal Cancer: On the Hinge Between Genetics and Epigenetics?. <i>EBioMedicine</i> , 2017, 21, 45-46.	2.7	4

#	ARTICLE	IF	CITATIONS
181	GC-MS metabolomics-based approach for the identification of a potential VOC biomarker panel in the urine of renal cell carcinoma patients. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2092-2105.	1.6	64
182	Glucose diffusion in colorectal mucosa—a comparative study between normal and cancer tissues. <i>Journal of Biomedical Optics</i> , 2017, 22, 091506.	1.4	35
183	<sc>NUT</sc> midline carcinoma of the larynx: an international series and review of the literature. <i>Histopathology</i> , 2017, 70, 861-868.	1.6	39
184	<i>POLE</i> somatic mutations in advanced colorectal cancer. <i>Cancer Medicine</i> , 2017, 6, 2966-2971.	1.3	43
185	Mesenchymal Stem Cells Relevance in Multicellular Bioengineered 3D In Vitro Tumor Models. <i>Biotechnology Journal</i> , 2017, 12, 1700079.	1.8	10
186	Long-Term Outcomes of Gastric Endoscopic Submucosal Dissection: Focus on Metachronous and Non-Curative Resection Management. <i>GE Portuguese Journal of Gastroenterology</i> , 2017, 24, 31-39.	0.3	30
187	<i>SETDB2</i> and <i>RIOX2</i> are differentially expressed among renal cell tumor subtypes, associating with prognosis and metastization. <i>Epigenetics</i> , 2017, 12, 1057-1064.	1.3	18
188	Identification of clear cell renal cell carcinoma and oncocytoma using a three-gene promoter methylation panel. <i>Journal of Translational Medicine</i> , 2017, 15, 149.	1.8	20
189	Epigenetic disruption of miR-130a promotes prostate cancer by targeting SEC23B and DEPDC1. <i>Cancer Letters</i> , 2017, 385, 150-159.	3.2	70
190	Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems. <i>Translational Research</i> , 2017, 180, 1-11.	2.2	29
191	Performance of Lynch syndrome predictive models in quantifying the likelihood of germline mutations in patients with abnormal MLH1 immunorexpression. <i>Familial Cancer</i> , 2017, 16, 73-81.	0.9	2
192	Testicular Germ Cell Tumors Go Epigenetics: Will miR-371a-3p Replace Classical Serum Biomarkers?. <i>European Urology</i> , 2017, 71, 221-222.	0.9	16
193	P3.01-049 T790M Mutation Detection, Clinical Characteristics and Impact in NSCLC Patients Treated with EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2220-S2221.	0.5	0
194	Simple multimodal optical technique for evaluation of free/bound water and dispersion of human liver tissue. <i>Journal of Biomedical Optics</i> , 2017, 22, 1.	1.4	24
195	Expression of ribosomal proteins in normal and cancerous human prostate tissue. <i>PLoS ONE</i> , 2017, 12, e0186047.	1.1	58
196	Water Content and Scatterers Dispersion Evaluation in Colorectal Tissues. <i>Journal of Biomedical Photonics and Engineering</i> , 2017, 3, 040301.	0.4	13
197	Epididymal metastasis from prostate adenocarcinoma: An unusual and challenging diagnosis suspected in gallium-68 prostate-specific membrane antigen-positron emission tomography/computed tomography and histologically confirmed. <i>Urology Annals</i> , 2017, 9, 89.	0.3	8
198	Bladder Cancer Pathology. , 2017, , 537-545.		0

#	ARTICLE	IF	CITATIONS
199	DNA Methylation Alterations as Biomarkers for Prostate Cancer. , 2016, , 275-296.		1
200	Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 459.	0.7	2
201	<i>NCOA2</i> is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 365-374.	1.5	14
202	Biomarkers in bladder cancer: A metabolomic approach using <i>in vitro</i> and <i>ex vivo</i> model systems. <i>International Journal of Cancer</i> , 2016, 139, 256-268.	2.3	62
203	Patterns of recurrence and treatment in male breast cancer: A clue to prognosis?. <i>International Journal of Cancer</i> , 2016, 139, 1715-1720.	2.3	12
204	Deciphering the function of non-coding RNAs in prostate cancer. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 235-262.	2.7	20
205	Epigenetic modulators as therapeutic targets in prostate cancer. <i>Clinical Epigenetics</i> , 2016, 8, 98.	1.8	68
206	Immune response and innervation signatures in aseptic hip implant loosening. <i>Journal of Translational Medicine</i> , 2016, 14, 205.	1.8	23
207	Comprehensive Analysis of Secreted Protein, Acidic and Rich in Cysteine in Prostate Carcinogenesis: Development of a 3D Nanostructured Bone-Like Model. <i>Journal of Biomedical Nanotechnology</i> , 2016, 12, 1667-1678.	0.5	5
208	Decoding the usefulness of non-coding RNAs as breast cancer markers. <i>Journal of Translational Medicine</i> , 2016, 14, 265.	1.8	58
209	Nuclear Magnetic Resonance metabolomics reveals an excretory metabolic signature of renal cell carcinoma. <i>Scientific Reports</i> , 2016, 6, 37275.	1.6	36
210	Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic <i>TMPRSS2:ERG</i> fusion status. <i>Human Molecular Genetics</i> , 2016, 25, ddw349.	1.4	8
211	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , 2016, 14, 66.	2.3	42
212	Is There a Role for Exosome-derived MicroRNAs in Detection of Renal Cell Tumors Using Urine Samples? Editorial to [European Urology Focus 2/2 (2016) 210â€“218]. <i>European Urology Focus</i> , 2016, 2, 654-655.	1.6	0
213	Male breast cancer: Looking for better prognostic subgroups. <i>Breast</i> , 2016, 26, 18-24.	0.9	34
214	Mucosal Prolapse Polyp Mimicking Rectal Malignancy: A Case Report. <i>GE Portuguese Journal of Gastroenterology</i> , 2016, 23, 214-217.	0.3	9
215	Co-occurrence of nonsense mutations in <i>MSH6</i> and <i>MSH2</i> in Lynch syndrome families evidencing that not all truncating mutations are equal. <i>Journal of Human Genetics</i> , 2016, 61, 151-156.	1.1	8
216	The role of germline mutations in the <i>BRCA1/2</i> and mismatch repair genes in men ascertained for early-onset and/or familial prostate cancer. <i>Familial Cancer</i> , 2016, 15, 111-121.	0.9	26

#	ARTICLE	IF	CITATIONS
217	Wavelength dependence of the refractive index of human colorectal tissues: comparison between healthy mucosa and cancer. <i>Journal of Biomedical Photonics and Engineering</i> , 2016, 2, 040307.	0.4	24
218	Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancer. <i>Oncotarget</i> , 2016, 7, 53018-53028.	0.8	46
219	Histone Posttranslational Modifications and Chromatin Remodelers in Prostate Cancer. , 2016, , 447-465.		0
220	Prognostic significance of MST1R dysregulation in renal cell tumors. <i>American Journal of Cancer Research</i> , 2016, 6, 1799-811.	1.4	3
221	MST1R methylation as a diagnostic biomarker in renal cell tumors. <i>Acta Urológica Portuguesa</i> , 2015, 32, 64-64.	0.1	2
222	Targets of Wnt/β-Catenin Transcription in Penile Carcinoma. <i>PLoS ONE</i> , 2015, 10, e0124395.	1.1	25
223	Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0132728.	1.1	34
224	MicroRNA-375 plays a dual role in prostate carcinogenesis. <i>Clinical Epigenetics</i> , 2015, 7, 42.	1.8	88
225	Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 723-733.	1.6	58
226	A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. <i>Cancer Discovery</i> , 2015, 5, 368-379.	7.7	56
227	212 Management and Long-Term Outcomes After Gastric Endoscopic Submucosal Dissection in an European Center. <i>Gastrointestinal Endoscopy</i> , 2015, 81, AB125.	0.5	1
228	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , 2015, 26, 1603-1616.	0.8	77
229	Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication. <i>Epigenetics</i> , 2015, 10, 1033-1043.	1.3	51
230	New insights on chromatin modifiers and histone posttranslational modifications in renal cell tumours. <i>European Journal of Clinical Investigation</i> , 2015, 45, 16-24.	1.7	12
231	Target gene mutational pattern in Lynch syndrome colorectal carcinomas according to tumour location and germline mutation. <i>British Journal of Cancer</i> , 2015, 113, 686-692.	2.9	30
232	Diagnostic and prognostic epigenetic biomarkers in cancer. <i>Epigenomics</i> , 2015, 7, 1003-1015.	1.0	173
233	Phenotypic impact of deregulated expression of class I histone deacetylases in urothelial cell carcinoma of the bladder. <i>Molecular Carcinogenesis</i> , 2015, 54, 523-531.	1.3	11
234	Identification of previously unrecognized FAP in children with Gardner fibroma. <i>European Journal of Human Genetics</i> , 2015, 23, 715-718.	1.4	11

#	ARTICLE	IF	CITATIONS
235	Altered Expression of Histone Deacetylases in Cancer. <i>Critical Reviews in Oncogenesis</i> , 2015, 20, 19-34.	0.2	21
236	Uncovering potential downstream targets of oncogenic GRPR overexpression in prostate carcinomas harboring ETS rearrangements. <i>Oncoscience</i> , 2015, 2, 497-507.	0.9	11
237	SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3. <i>Oncotarget</i> , 2015, 6, 13644-13657.	0.8	69
238	Male breast cancer: Looking for prognostic subgroups.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11562-e11562.	0.8	0
239	Frozen in Translation: Biobanks as a Tool for Cancer Research. <i>Journal of Intellectual Disability - Diagnosis and Treatment</i> , 2015, 3, 51-62.	0.1	1
240	Anti-neoplastic properties of hydralazine in prostate cancer. <i>Oncotarget</i> , 2014, 5, 5950-5964.	0.8	48
241	Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1349-1358.	1.1	8
242	Biopsy sampling and histopathological markers for diagnosis of prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 1323-1336.	1.1	3
243	DNA hypomethylation in plasma as a cancer biomarker: when less is more?. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 419-422.	1.5	2
244	Familial vs sporadic papillary thyroid carcinoma: a matched-case comparative study showing similar clinical/prognostic behaviour. <i>European Journal of Endocrinology</i> , 2014, 170, 321-327.	1.9	40
245	Enteropathy-associated T cell lymphoma as a complication of silent celiac disease. <i>Hematology Reports</i> , 2014, 6, 5612.	0.3	3
246	Analysis of volatile human urinary metabolome by solid-phase microextraction in combination with gas chromatography-mass spectrometry for biomarker discovery: Application in a pilot study to discriminate patients with renal cell carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 1993-2002.	1.3	54
247	Pathogenicity Evaluation of BRCA1 and BRCA2 Unclassified Variants Identified in Portuguese Breast/Ovarian Cancer Families. <i>Journal of Molecular Diagnostics</i> , 2014, 16, 324-334.	1.2	24
248	Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. <i>Endocrine-Related Cancer</i> , 2014, 21, 51-61.	1.6	76
249	External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1804-1812.	1.1	44
250	T-box Transcription Factor Brachyury Is Associated with Prostate Cancer Progression and Aggressiveness. <i>Clinical Cancer Research</i> , 2014, 20, 4949-4961.	3.2	67
251	Accurate detection of upper tract urothelial carcinoma in tissue and urine by means of quantitative GDF15, TMEFF2 and VIM promoter methylation. <i>European Journal of Cancer</i> , 2014, 50, 226-233.	1.3	47
252	Epigenetic biomarkers in urological tumors: A systematic review. <i>Cancer Letters</i> , 2014, 342, 264-274.	3.2	82

#	ARTICLE	IF	CITATIONS
253	Epigenetic regulation of <i>EFEMP1</i> in prostate cancer: biological relevance and clinical potential. <i>Journal of Cellular and Molecular Medicine</i> , 2014, 18, 2287-2297.	1.6	23
254	Anti-Tumoral Effect of the Non-Nucleoside DNMT Inhibitor RG108 in Human Prostate Cancer Cells. <i>Current Pharmaceutical Design</i> , 2014, 20, 1803-1811.	0.9	48
255	Bladder Cancer Pathology. , 2014, , 1-11.		0
256	Relapsed Follicular Lymphoma Treatment - with or without Hematopoietic Stem Cell Transplant?. <i>Blood</i> , 2014, 124, 5893-5893.	0.6	0
257	Advanced Stage Follicular Lymphoma - Watch and Wait or Immunochemotherapy?. <i>Blood</i> , 2014, 124, 5476-5476.	0.6	0
258	High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer. <i>BMC Cancer</i> , 2013, 13, 169.	1.1	44
259	Frequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes. <i>Breast Cancer Research and Treatment</i> , 2013, 138, 37-45.	1.1	36
260	Epigenetic regulation of MDR1 gene through post-translational histone modifications in prostate cancer. <i>BMC Genomics</i> , 2013, 14, 898.	1.2	62
261	A panel of four immunohistochemical markers (CK7, CK20, TTF-1, and p63) allows accurate diagnosis of primary and metastatic lung carcinoma on biopsy specimens. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 749-754.	1.4	36
262	A founder SDHB mutation in Portuguese paraganglioma patients. <i>Endocrine-Related Cancer</i> , 2013, 20, L23-L26.	1.6	12
263	The <i>MSH2</i> c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families. <i>Clinical Genetics</i> , 2013, 84, 244-250.	1.0	13
264	<i>Helicobacter pylori</i> Induces Increased Expression of Toll-Like Receptors and Decreased Toll-Interacting Protein in Gastric Mucosa that Persists Throughout Gastric Carcinogenesis. <i>Helicobacter</i> , 2013, 18, 22-32.	1.6	54
265	Novel 5q22 Fusion Partners of ETV1 and ETV4 in Prostate Cancer. <i>Neoplasia</i> , 2013, 15, 720-IN6.	2.3	36
266	Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. <i>Prostate</i> , 2013, 73, 763-769.	1.2	40
267	MicroRNA profile: a promising ancillary tool for accurate renal cell tumour diagnosis. <i>British Journal of Cancer</i> , 2013, 109, 2646-2653.	2.9	71
268	Deregulation of <i>PAX2</i> expression in renal cell tumours: mechanisms and potential use in differential diagnosis. <i>Journal of Cellular and Molecular Medicine</i> , 2013, 17, 1048-1058.	1.6	16
269	Enoxacin inhibits growth of prostate cancer cells and effectively restores microRNA processing. <i>Epigenetics</i> , 2013, 8, 548-558.	1.3	49
270	Altered Expression of MGMT in High-Grade Gliomas Results from the Combined Effect of Epigenetic and Genetic Aberrations. <i>PLoS ONE</i> , 2013, 8, e58206.	1.1	28

#	ARTICLE	IF	CITATIONS
271	Regulation of histone H2A.Z expression is mediated by sirtuin 1 in prostate cancer. <i>Oncotarget</i> , 2013, 4, 1673-1685.	0.8	45
272	Proliferative Activity Of Neoplastic B Cells - Impact On The Prognosis Of Follicular Lymphoma. <i>Blood</i> , 2013, 122, 4321-4321.	0.6	0
273	Increased hepatic expression of TLR2 and TLR4 in the hepatic inflammation-fibrosis-carcinoma sequence. <i>Innate Immunity</i> , 2012, 18, 700-708.	1.1	58
274	A multicenter validation of an endoscopic classification with narrow band imaging for gastric precancerous and cancerous lesions. <i>Endoscopy</i> , 2012, 44, 236-246.	1.0	151
275	Moving forward in bladder cancer detection and diagnosis: the role of epigenetic biomarkers. <i>Expert Review of Molecular Diagnostics</i> , 2012, 12, 871-878.	1.5	8
276	Further insights into chemical characterization through GC-MS and evaluation for anticancer potential of <i>Dracaena draco</i> leaf and fruit extracts. <i>Food and Chemical Toxicology</i> , 2012, 50, 3847-3852.	1.8	8
277	Molecular Subtyping of Primary Prostate Cancer Reveals Specific and Shared Target Genes of Different ETS Rearrangements. <i>Neoplasia</i> , 2012, 14, 600-IN15.	2.3	63
278	Decreased Toll-interacting protein and peroxisome proliferator-activated receptor β are associated with increased expression of Toll-like receptors in colon carcinogenesis. <i>Journal of Clinical Pathology</i> , 2012, 65, 302-308.	1.0	37
279	The Epigenetics of Renal Cell Tumors: from Biology to Biomarkers. <i>Frontiers in Genetics</i> , 2012, 3, 94.	1.1	29
280	<i>FLI1</i> is a novel ETS transcription factor involved in gene fusions in prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 240-249.	1.5	73
281	Cocaine-induced kidney toxicity: an in vitro study using primary cultured human proximal tubular epithelial cells. <i>Archives of Toxicology</i> , 2012, 86, 249-261.	1.9	43
282	Potential Downstream Target Genes of Aberrant ETS Transcription Factors Are Differentially Affected in Ewing's Sarcoma and Prostate Carcinoma. <i>PLoS ONE</i> , 2012, 7, e49819.	1.1	21
283	Low-Dose Radiotherapy in Patients with Non Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 4875-4875.	0.6	0
284	Detection of Promoter Hypermethylation in Salivary Rinses as a Biomarker for Head and Neck Squamous Cell Carcinoma Surveillance. <i>Clinical Cancer Research</i> , 2011, 17, 4782-4789.	3.2	84
285	Cysteine-Rich Secretory Protein-3 (CRISP3) Is Strongly Up-Regulated in Prostate Carcinomas with the TMPRSS2-ERG Fusion Gene. <i>PLoS ONE</i> , 2011, 6, e22317.	1.1	36
286	Functional and Epigenetic Characterization of the <i>KRT19</i> Gene in Renal Cell Neoplasms. <i>DNA and Cell Biology</i> , 2011, 30, 85-90.	0.9	12
287	Comparison of methodologies for KRAS mutation detection in metastatic colorectal cancer. <i>Cancer Genetics</i> , 2011, 204, 439-446.	0.2	37
288	Biological activities of Portuguese propolis: Protection against free radical-induced erythrocyte damage and inhibition of human renal cancer cell growth in vitro. <i>Food and Chemical Toxicology</i> , 2011, 49, 86-92.	1.8	106

#	ARTICLE	IF	CITATIONS
289	Prognostic value of opioid binding protein/cell adhesion molecule-like promoter methylation in bladder carcinoma. <i>European Journal of Cancer</i> , 2011, 47, 1106-1114.	1.3	31
290	<i>TCF21</i> and <i>PCDH17</i> methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. <i>Epigenetics</i> , 2011, 6, 1120-1130.	1.3	99
291	A Rapid and Simple Procedure for the Establishment of Human Normal and Cancer Renal Primary Cell Cultures from Surgical Specimens. <i>PLoS ONE</i> , 2011, 6, e19337.	1.1	53
292	Detection of colon cancer by terahertz techniques. , 2011, , .		13
293	Detection of colon cancer by terahertz techniques. <i>Journal of Molecular Structure</i> , 2011, 1006, 77-82.	1.8	163
294	Epigenetics in Prostate Cancer: Biologic and Clinical Relevance. <i>European Urology</i> , 2011, 60, 753-766.	0.9	187
295	High RASSF1A promoter methylation levels are predictive of poor prognosis in fine-needle aspirate washings of breast cancer lesions. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 1-9.	1.1	31
296	Increased Expression of Toll-like Receptors (TLR) 2, 4 and 5 in Gastric Dysplasia. <i>Pathology and Oncology Research</i> , 2011, 17, 677-83.	0.9	62
297	Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. <i>BMC Cancer</i> , 2011, 11, 312.	1.1	147
298	Relative 8q gain predicts disease-specific survival irrespective of the <i>TMPRSS2-ERG</i> fusion status in diagnostic biopsies of prostate cancer. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 662-671.	1.5	24
299	MSI phenotype and MMR alterations in familial and sporadic gastric cancer. <i>International Journal of Cancer</i> , 2011, 128, 1606-1613.	2.3	65
300	Discriminating adenocarcinoma from normal colonic mucosa through deconvolution of Raman spectra. <i>Journal of Biomedical Optics</i> , 2011, 16, 127001.	1.4	17
301	A novel exonic rearrangement affecting MLH1 and the contiguous LRRFIP2 is a founder mutation in Portuguese Lynch syndrome families. <i>Genetics in Medicine</i> , 2011, 13, 895-902.	1.1	21
302	Detailed analysis of expression and promoter methylation status of apoptosis-related genes in prostate cancer. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2010, 15, 956-965.	2.2	37
303	Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients. <i>BMC Cancer</i> , 2010, 10, 470.	1.1	17
304	Colorectal carcinomas with microsatellite instability display a different pattern of target gene mutations according to large bowel site of origin. <i>BMC Cancer</i> , 2010, 10, 587.	1.1	28
305	Feasibility of differential diagnosis of kidney tumors by comparative genomic hybridization of fine needle aspiration biopsies. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 935-947.	1.5	41
306	Three Epigenetic Biomarkers, <i>GDF15</i> , <i>TMEFF2</i> , and <i>VIM</i> , Accurately Predict Bladder Cancer from DNA-Based Analyses of Urine Samples. <i>Clinical Cancer Research</i> , 2010, 16, 5842-5851.	3.2	155

#	ARTICLE	IF	CITATIONS
307	Epigenetic regulation of Wnt signaling pathway in urological cancer. <i>Epigenetics</i> , 2010, 5, 343-351.	1.3	34
308	Acute phosphate nephropathy after bowel cleansing: still a menace. <i>Nefrologia</i> , 2010, 30, 702-4.	0.2	6
309	Haplotype and quantitative transcript analyses of Portuguese breast/ovarian cancer families with the BRCA1 R71G founder mutation of Galician origin. <i>Familial Cancer</i> , 2009, 8, 203-208.	0.9	11
310	CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas. <i>Modern Pathology</i> , 2009, 22, 744-752.	2.9	23
311	GSTP1 Hypermethylation for Prostate Cancer Detection. , 2009, , 279-288.		2
312	Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions. <i>Breast Cancer Research and Treatment</i> , 2008, 109, 27-34.	1.1	47
313	Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate cancer. <i>Prostate</i> , 2008, 68, 418-426.	1.2	38
314	Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor. <i>Pediatric Blood and Cancer</i> , 2008, 51, 554-557.	0.8	8
315	Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2008, 14, 97-107.	3.2	163
316	ssDNA-Binding Protein 2 Is Frequently Hypermethylated and Suppresses Cell Growth in Human Prostate Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 3754-3760.	3.2	32
317	Genome-Wide Promoter Analysis Uncovers Portions of the Cancer Methylome. <i>Cancer Research</i> , 2008, 68, 2661-2670.	0.4	131
318	Overexpression of the Mitotic Checkpoint Genes <i>BUB1</i> and <i>BUBR1</i> is Associated with Genomic Complexity in Clear Cell Kidney Carcinomas. <i>Analytical Cellular Pathology</i> , 2008, 30, 389-395.	0.7	3
319	Overexpression of the mitotic checkpoint genes <i>BUB1</i> and <i>BUBR1</i> is associated with genomic complexity in clear cell kidney carcinomas. <i>Cellular Oncology</i> , 2008, 30, 389-95.	1.9	36
320	Array-Based Comparative Genomic Hybridization in Prostate Cancer: Research and Clinical Applications. , 2008, , 415-429.		0
321	High Promoter Methylation Levels of APC Predict Poor Prognosis in Sextant Biopsies from Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2007, 13, 6122-6129.	3.2	122
322	A Clinical Case of Castleman's Disease. <i>Journal of Thoracic Oncology</i> , 2007, 2, 259-260.	0.5	9
323	Minimal change nephrotic syndrome after stem cell transplantation: a case report and literature review. <i>Journal of Medical Case Reports</i> , 2007, 1, 121.	0.4	14
324	Epigenetic Markers for Molecular Detection of Prostate Cancer. <i>Disease Markers</i> , 2007, 23, 31-41.	0.6	48

#	ARTICLE	IF	CITATIONS
325	NEW DOCTORIAL CANCER RESEARCH: Epigenetic Heterogeneity in Prostate Cancer: Impact of Genetic and Epigenetic Alterations on Diagnosis and Prognosis. <i>Critical Reviews in Oncogenesis</i> , 2007, 13, 181-183.	0.2	0
326	Positive Correlation of Tissue Inhibitor of Metalloproteinase-3 and Death-Associated Protein Kinase Hypermethylation in Head and Neck Squamous Cell Carcinoma. <i>Laryngoscope</i> , 2007, 117, 1376-1380.	1.1	18
327	Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. <i>BMC Cancer</i> , 2007, 7, 133.	1.1	58
328	Relative Copy Number Gain of MYC in Diagnostic Needle Biopsies is an Independent Prognostic Factor for Prostate Cancer Patients. <i>European Urology</i> , 2007, 52, 116-125.	0.9	49
329	Expression changes of the MAD mitotic checkpoint gene family in renal cell carcinomas characterized by numerical chromosome changes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 379-385.	1.4	17
330	Methylation-Based Biomarkers for Early Detection of Urological Cancer. <i>Critical Reviews in Oncogenesis</i> , 2007, 13, 265-282.	0.2	10
331	TMPRSS2-ERG Gene Fusion Causing ERG Overexpression Precedes Chromosome Copy Number Changes in Prostate Carcinomas, Paired HGPIN Lesions. <i>Neoplasia</i> , 2006, 8, 826-832.	2.3	225
332	Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. <i>Molecular Cancer</i> , 2006, 5, 33.	7.9	19
333	Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. <i>Journal of Molecular Medicine</i> , 2006, 84, 911-918.	1.7	54
334	Statistical dissection of genetic pathways involved in prostate carcinogenesis. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 154-163.	1.5	44
335	Deleted in Colorectal Cancer Is a Putative Conditional Tumor-Suppressor Gene Inactivated by Promoter Hypermethylation in Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2006, 66, 9401-9407.	0.4	63
336	Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate Carcinogenesis. <i>Molecular Cancer Research</i> , 2006, 4, 1-8.	1.5	85
337	8q Gain Is an Independent Predictor of Poor Survival in Diagnostic Needle Biopsies from Prostate Cancer Suspects. <i>Clinical Cancer Research</i> , 2006, 12, 3961-3970.	3.2	65
338	Postnatal cerebellar granule cells of the white rat (<i>Rattus norvegicus</i>): a quantitative study, using design-based stereology. <i>Annals of Anatomy</i> , 2005, 187, 161-173.	1.0	2
339	Multimodal genetic diagnosis of solid variant alveolar rhabdomyosarcoma. <i>Cancer Genetics and Cytogenetics</i> , 2005, 163, 138-143.	1.0	13
340	Tubular Kidney Damage and Centrilobular Liver Injury after Intratracheal Instillation of Dimethyl Selenide. <i>Toxicologic Pathology</i> , 2005, 33, 225-229.	0.9	3
341	Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects. <i>Journal of Clinical Oncology</i> , 2005, 23, 6569-6575.	0.8	227
342	Frequent 14-3-3 If Promoter Methylation in Benign and Malignant Prostate Lesions. <i>DNA and Cell Biology</i> , 2005, 24, 264-269.	0.9	60

#	ARTICLE	IF	CITATIONS
343	MT1G Hypermethylation Is Associated with Higher Tumor Stage in Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 1274-1278.	1.1	65
344	The loss of NKX3.1 expression in testicular--and prostate--cancers is not caused by promoter hypermethylation. <i>Molecular Cancer</i> , 2005, 4, 8.	7.9	8
345	Quantitative RAR β 2 Hypermethylation. <i>Clinical Cancer Research</i> , 2004, 10, 4010-4014.	3.2	117
346	A Quantitative Promoter Methylation Profile of Prostate Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 8472-8478.	3.2	234
347	Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer. <i>Journal of Clinical Pathology</i> , 2004, 57, 872-876.	1.0	50
348	BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. <i>Modern Pathology</i> , 2004, 17, 1359-1363.	2.9	161
349	Molecular Detection of Prostate Cancer: A Role for GSTP1 Hypermethylation. <i>European Urology</i> , 2004, 46, 660-669.	0.9	119
350	Highly sensitive detection of the MGB1 transcript (mammaglobin) in the peripheral blood of breast cancer patients. <i>International Journal of Cancer</i> , 2004, 108, 592-595.	2.3	27
351	Identification of AIM1 as a Hypermethylation-Inactivated Tumor Suppressor Gene in HNSCC. <i>Otolaryngology - Head and Neck Surgery</i> , 2004, 131, P173-P174.	1.1	1
352	Uses of DNA Methylation in Cancer Diagnosis and Risk Assessment. , 2004, , 11-26.		5
353	Karyotypic divergence and convergence in two synchronous lung metastases of a clear cell sarcoma of tendons and aponeuroses with t(12;22)(q13;q12) and type 1 EWS/ATF1. <i>Cancer Genetics and Cytogenetics</i> , 2003, 145, 121-125.	1.0	5
354	Mucosa-associated lymphoid-tissue lymphoma. Should we perform a colonoscopy in multiorgan involvement?. <i>Digestive Endoscopy</i> , 2003, 15, 232-234.	1.3	0
355	Biallelic inactivation of the RIZ1 gene in human gastric cancer. <i>Oncogene</i> , 2003, 22, 6954-6958.	2.6	52
356	A New Approach to an Unbiased Estimate of the Hepatic Stellate Cell Index in the Rat Liver: An Example in Healthy Conditions1. <i>Journal of Histochemistry and Cytochemistry</i> , 2003, 51, 1101-1104.	1.3	11
357	Toxic effects of selenium inhalation: acute damage of the respiratory system of mice. <i>Human and Experimental Toxicology</i> , 2003, 22, 551-557.	1.1	8
358	Endothelin B receptor gene hypermethylation in prostate adenocarcinoma. <i>Journal of Clinical Pathology</i> , 2003, 56, 52-55.	1.0	48
359	Detection of gene promoter hypermethylation in fine needle washings from breast lesions. <i>Clinical Cancer Research</i> , 2003, 9, 3413-7.	3.2	54
360	Endoscopic Ultrasonography in Multiple Lymphomatous Polyposis. <i>Journal of Clinical Gastroenterology</i> , 2002, 34, 150-154.	1.1	2

#	ARTICLE	IF	CITATIONS
361	Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. <i>Urology</i> , 2002, 60, 1131-1135.	0.5	196
362	Apocrine ductal carcinoma in situ of the breast: Histologic classification and expression of biologic markers. <i>Human Pathology</i> , 2001, 32, 487-493.	1.1	90
363	Age-related changes in rat cerebellar basket cells: a quantitative study using unbiased stereological methods. <i>Journal of Anatomy</i> , 2001, 198, 727-736.	0.9	6
364	Mitochondrial mutations in early stage prostate cancer and bodily fluids. <i>Oncogene</i> , 2001, 20, 5195-5198.	2.6	220
365	Quantitation of GSTP1 Methylation in Non-neoplastic Prostatic Tissue and Organ-Confined Prostate Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2001, 93, 1747-1752.	3.0	281
366	Quantitative age-changes in endoplasmic reticulum and nucleus of cerebellar granule cells†. <i>Neurobiology of Aging</i> , 2000, 21, 97-105.	1.5	5
367	Prognostic value of Ki-67 expression in localized cutaneous malignant melanoma. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 991-1000.	0.6	48
368	Guidelines for subtyping small B-cell lymphomas in bone marrow biopsies. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 1999, 435, 549-558.	1.4	25
369	Immunophenotyping by flow cytometry of fine needle aspirates in the diagnosis of lymphoproliferative disorders: A retrospective study. , 1999, 13, 224-228.		26
370	Age-related changes in the volume of somata and organelles of cerebellar granule cells. <i>Neurobiology of Aging</i> , 1998, 19, 325-332.	1.5	13
371	A Stereological Study on the Nuclear Volume of Cerebellar Granule Cells in Aging Rats. <i>Neurobiology of Aging</i> , 1997, 18, 199-203.	1.5	16
372	Squamous Cell Carcinoma of the Cervix Metastatic to the Spleen—Case Report. <i>Gynecologic Oncology</i> , 1997, 67, 107-110.	0.6	15
373	Gastric MALT Lymphoma: A 8-Year Experience. <i>Indian Journal of Hematology and Blood Transfusion</i> , 0, , 1.	0.3	0
374	DigiMir Test: Establishing a Novel Pipeline for MiR-371a Quantification Using Droplet Digital PCR in Liquid Biopsies From Testicular Germ Cell Tumor Patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	11